Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai - ...

"After re-examining its initial opinion, the EMA... has recommended granting marketing authorisation to Leqembi (lecanemab) ...

Northern Light Mayo Hospital will hold a small emergency preparedness drill in the Corinth area Thursday afternoon (11/14).

At the core of Sasseur REIT’s success is its Entrusted Management Agreement (EMA) model, a key differentiator from other ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

The agency had previously recommended against marketing authorization for the Alzheimer's disease but reconsidered after a review.

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

This is despite no scientific proof that there is alien life on other planets. University of Birmingham philosopher Dr Ema ...

The 50-day EMA currently sits right around the $71.20 level and is dropping so I think that’s something that you need to be ...

The silver market continues to see a lot of downward pressure, as the market continues to work against the precious metals ...

Ema Stokholma, engaged every day with the program “Radio 2 Social Club”, is a guest today on La Volta Buona, the program ...

The trends on Gift Nifty also indicate a weak start for the Indian benchmark index. The Gift Nifty was trading around 23,620 ...